

Decidual soluble factors participate in the control of HIV-1 infection at the maternofetal interface

Marlin *et al.*



RESEARCH

Open Access

Decidual soluble factors participate in the control of HIV-1 infection at the maternofetal interface

Romain Marlin^{1†}, Marie-Thérèse Nugeyre^{1†}, Marion Duriez¹, Claude Cannou¹, Anne Le Breton², Nadia Berkane³, Françoise Barré-Sinoussi¹ and Elisabeth Menu^{1*}

Abstract

Background: Maternofetal transmission (MFT) of HIV-1 is relatively rare during the first trimester of pregnancy despite the permissivity of placental cells for cell-to-cell HIV-1 infection. Invasive placental cells interact directly with decidual cells of the uterine mucosa during the first months of pregnancy, but the role of the decidua in the control of HIV-1 transmission is unknown.

Results: We found that decidual mononuclear cells naturally produce low levels of IL-10, IL-12, IL-15, TNF- α , IFN- α , IFN- γ and CXCL-12 (SDF-1), and large amounts of CCL-2 (MCP1), CCL-3 (MIP-1 α), CCL-4 (MIP-1 β), CCL-5 (Rantes), CXCL-10 (IP-10), IL-6 and IL-8. CCL-3 and CCL-4 levels were significantly upregulated by *in vitro* infection with R5 HIV-1 but not X4. Decidual CD14+ antigen presenting cells were the main CCL-3 and CCL-4 producers among decidual leukocytes. R5 and X4 HIV-1 infection was inhibited by decidual cell culture supernatants *in vitro*. Using HIV-1 pseudotypes, we found that inhibition of the HIV-1 entry step was inhibited by decidual soluble factors.

Conclusion: Our findings show that decidual innate immunity (soluble factors) is involved in the control of HIV-1 infection at the maternofetal interface. The decidua could thus serve as a mucosal model for identifying correlates of protection against HIV-1 infection.

Background

Cytokines are involved in cell activation, immune response polarization and antiviral immunity, and play a key role in innate immunity. In particular, cytokines and chemokines can interfere with several steps of the Human Immunodeficiency Virus type 1 (HIV-1) replicative cycle. For instance, type 1 interferon (IFN) can induce the transcription of more than 100 genes, such as *Mx1*, *OAS* or *TRIM5 α* , thereby inhibiting reverse transcription [1] and provirus integration [2]. Some chemokines inhibit HIV-1 entry by competitive binding to viral co-receptors [3,4]: CCL-3, CCL-4 and CCL-5 interact with the CCR5 co-receptor, thereby inhibiting the entry of R5 HIV-1, while CXCL-12 binds to CXCR4 and thus inhibits X4 HIV-1 entry. In contrast, proinflammatory cytokines such as IL-6, IL-12 and TNF- α stimulate HIV-1 replication by promoting inflammation or proviral genome transcription [5-7].

Cytokines are also involved in physiological processes, for example regulating blastocyst implantation during the first trimester of pregnancy [8], as well as placental invasion [9] and tolerance of the fetus [10].

Maternofetal transmission (MFT) of HIV-1 is relatively rare, even in the absence of antiretroviral therapy. R5 HIV-1 isolates are found in most cases of mother-to-child transmission [11-16], and MFT usually occurs during the last trimester [17] pointing to the existence of effective natural control mechanisms particularly during the first months of pregnancy. During the first trimester of pregnancy the maternofetal interface is composed of the placenta (the fetal part) and the maternal uterine mucosa (decidua) [18]. Decidual tissue is defined by its location and function: the decidua basalis is located at the implantation site, in close contact with the placenta, while the decidua parietalis lines the rest of the uterine wall [19]. Blastocyst attachment to the decidua induces placental cell differentiation. A contingent of placental cells, known as extravillous trophoblast cells, invades the decidua during the first trimester of pregnancy.

* Correspondence: elisabeth.menu@pasteur.fr

† Contributed equally

¹Regulation of Retroviral Infection Unit, Department of virology, Institut Pasteur, Paris, France

Full list of author information is available at the end of the article

Immune cells represent a large component of decidual tissue and are composed of natural killer cells (dNK), antigen-presenting cells (dAPC), T lymphocytes (dT) and small percentages of $\gamma\delta$ T lymphocytes and NKT cells [20]. These cells interact with one another and with invading trophoblast cells. Trophoblast cells are not permissive to cell-free HIV-1 infection [21,22] but interaction between trophoblast cells and HIV-1-infected cells allows infectious virions to cross the trophoblastic barrier in an *in vitro* model [23]. We have previously shown that first-trimester decidual tissue contains HIV-1 target cells. CD14⁺ dAPC are the main targets of R5 HIV-1, while decidual T lymphocytes are the main targets of X4 HIV-1 [24]. As MFT is rare during the first trimester of pregnancy, cell-to-cell HIV-1 dissemination at the maternofetal interface appears to be tightly controlled.

The aims of this study were to analyze decidual soluble factors and their role in the regulation of HIV-1 infection at the maternofetal interface.

Results

Characterization of the main decidual mononuclear cell populations

Fresh decidual samples were analyzed by immunohistochemistry. As expected, tissue contained cytokeratin 7⁺ placental cells and CD34⁺ endothelial cells. A high number of immune decidual cells were also visualized in isolated tissue (Figure 1); CD56⁺ NK cells, CD14⁺ antigen presenting cells and CD3⁺ T cells. After the digestion of the tissue, mononuclear cells were analyzed by flow cytometry. Immune cell populations present within the decidua are shown on Figure 2 from one representative experiment. As previously described [20,25,26], decidual CD3⁻/CD56⁺ NK cells represent the main leukocyte population in the decidual tissue (mean 58% \pm 7.8). Decidual leukocytes are also composed of CD14⁺ antigen presenting cells (mean 19% \pm 4.7) and CD3⁺ T lymphocytes (mean 8% \pm 5), including CD4⁺ and CD8⁺ T lymphocytes (n = 21). Altogether, these results confirmed that the studied tissue was the decidua basalis, a maternal tissue in direct contact with the placenta. Flow cytometry analyzes show that both leukocytes (CD45⁺) and non-leukocytes (CD45⁻) cells were present in decidual mononuclear cells and that dNK cells are the main leukocyte population.

Decidual culture supernatants contain soluble factors that regulate HIV-1 infection

To identify soluble factors secreted by decidual cells, we applied Luminex technology and ELISA methods to culture supernatants of decidua basalis mononuclear cells. Cytokines were quantified after 24 hours of culture without stimulation. Figure 3 shows the cytokines detected

according to their abundance: low (Figure 3A), medium (Figure 3B), and high (Figure 3C). Cytokines detected at low levels included IL-10 (mean 277 pg/ml \pm 72), IL-12 (456 pg/ml \pm 46), IL-15 (118 pg/ml \pm 14), TNF- α (372 pg/ml \pm 107), IFN- α (71 pg/ml \pm 6), IFN- γ (86 pg/ml \pm 8) and CXCL-12 (148 pg/ml \pm 36). Chemokines detected at moderate or high levels included CCL-3 (11460 pg/ml \pm 2367), CCL-4 (7272 pg/ml \pm 1760), CCL-5 (1492 pg/ml \pm 300), CXCL-10 (11300 pg/ml \pm 2260) and CCL-2 (106 ng/ml \pm 1.7). The pro-inflammatory cytokines IL-6 (33 ng/ml \pm 7.6) and IL-8 (3.10³ ng/ml \pm 953) were also abundant. The proinflammatory cytokine IL-2 was undetectable (data not show), in keeping with its known absence from the healthy maternofetal interface [27].

The detected soluble factors were also present in similar proportions, but at lower levels in decidua basalis and decidua parietalis histoculture supernatants (data not shown). IL-6 and IL-8 were significantly more abundant in decidua basalis supernatants than in decidua parietalis supernatants (p = 0.0012 and p = 0.01 respectively).

These results showed that decidual cells secreted soluble factors known to regulate HIV-1 infection, including β -chemokines known to inhibit R5 viral entry.

β -chemokine secretion increases during HIV-1 infection of decidual cells

Decidua basalis culture supernatants were analyzed with Luminex technology 14 days after infection, at a time of sustained HIV-1 replication. As the culture medium was renewed every 3 days, reported cytokine levels are those having accumulated between day 11 and day 14. CCL-3 and CCL-4 were significantly more abundant (p = 0.026 and p = 0.027) in the supernatants of R5 HIV-1-infected cells than of non-infected cells. CCL-5 was not significantly more abundant in R5 HIV-1-infected cell supernatants 14 days after infection (p = 0.06)(Figure 4A).

In contrast to R5 HIV-1-infected cells, cytokine secretion was not significantly modulated by X4 HIV-1 infection (Figure 4A and 4B). Production of IL-12, IL-6, CCL-2, CXCL-10 and CXCL-12, that were also detected at day 14, was not significantly affected by either R5 or X4 HIV-1 infection (data not show).

Thus, CCL-3 and CCL-4 release by cultured decidua basalis mononuclear cells was enhanced by R5 HIV-1 infection.

Decidual CD14⁺ cells are the main sources of CCL-3 and CCL-4

Luminex analysis showed that CCL-3 and CCL-4 release was increased by R5 HIV-1 infection. To identify the source of these chemokines, freshly isolated, HIV-1-uninfected decidua basalis mononuclear cells were analyzed by flow cytometry after intracellular staining. CCL-3 and






Figure 1 Characterization of decidual mononuclear cells by immunocytochemistry. Frozen decidua basalis sections were stained with Isotype matched Ig control (A), anti-CD34 (B), anti-Cytokeratin 7 (C), anti-CD14 (D), anti-CD56 (E) and anti-CD3 (F). Staining were visualized with diaminobenzidine (brown cells in B, D, E and F) or Vector red (red cells in C) chromogen and tissue sections were counterstained with haematoxylin. Images were taken at $\times 100$ (A, B, C and E) or $\times 200$ (D and F) magnification.

CCL-4 staining was observed in non leukocytic cells (CD45⁻), natural killer cells (CD56⁺ dNK), and antigen-presenting cells (CD14⁺ dAPC) (Figure 5A). The mean fluorescence indexes (MFI) of CCL-3 and CCL-4 in cells

from decidua from 4 different women were higher in dAPC than in non leukocytic and dNK cells (Figure 5B). CD4⁺ T cells and CD8⁺ T cells both had very low MFIs for CCL-3 and CCL-4.



To confirm the results of flow cytometry, CCL-3 and CCL-4 were quantified by Luminex analysis in 3-day culture supernatants of purified dAPC and dNK cells. Large amounts of both CCL-3 and CCL-4 were detected in dAPC supernatants (23 454 pg/ml \pm 12 214 and 10 496 pg/ml \pm 4 898, respectively) (Figure 5C). CCL-3 and CCL-4 were also found in dNK cell supernatants, but at lower levels (717 pg/ml \pm 314; and 1 445 pg/ml \pm 285, respectively). Small amounts of CCL-5 were found in



both dAPC and dNK supernatants (452 pg/ml \pm 325 and 291 pg/ml \pm 50, respectively).

These results showed that dAPC were the main sources of CCL-3 and CCL-4 in the decidua.

Decidual soluble factors can inhibit HIV-1 infection

To examine the role of the cytokine environment in the inhibition of viral replication, decidual mononuclear cells were cultured for 24 hours before infection with R5 HIV-1 or X4 HIV-1. The cells were then infected, following a washing step or without a washing step (i.e. in the presence or absence of their respective 24-hour supernatants). R5 HIV-1 infection of decidual mononuclear cells was inhibited, as shown by the p24 antigen assay 7 days post-infection, in experiments with 6 out of 9 donors (range 0 to 80%, mean 28.64% \pm 11.6; p = 0.039) (Figure 6). Inhibitory activity was lower 10 days post-infection (mean 18.69% \pm 9.6; p = 0.088).






Figure 4 Modulation of β -chemokine secretion by HIV-1 infection of decidual mononuclear cells. Decidual mononuclear cells were infected with R5 and X4 HIV-1 (10^{-3} MOI). (A) β -chemokine secretion was measured 14 days later, after 3 days of culture (day 11 to day 14): uninfected control conditions (black dots), R5 HIV-1 (red dots) and X4 HIV-1 (blue dots). Results are expressed in pg/ml, as measured with Luminex technology. Bars indicate the median values and each donor is represented by a different symbol. Significant changes are indicated. (B) Results are the fold increase in secretion in HIV-1-infected cell culture supernatants compared to uninfected controls. Bars represent the mean of the fold induction and error bars the SEM. At least 6 different donors were used for each experimental condition. Significant changes are indicated by a star ($p < 0.05$). A one-sample t test was used.






Inhibition of X4 HIV-1 infection was observed in experiments with 6 out of 9 donors, 10 days post-infection (mean 11.25% \pm 11.9; $p = 0.375$)(Figure 6); however, in contrast to the effect on R5 HIV-1 infection, the mean percentage of inhibition was not statistically significant.

To determine whether decidual soluble factors inhibited HIV-1 entry, the HeLa P4P cell line, which expresses the CD4 HIV receptor and also the co-receptors CCR5 and CXCR4, were infected by HIV-1 pseudotypes in the presence or absence of 24 h decidual conditioned medium (dCM). Efficiency of infection was measured in terms of luciferase activity (representative experiment in Figure 7A). dCM from 7 out of 8 donors significantly reduced R5 HIV-1_{BaL} pseudotype infection (mean 32.9% \pm 7, range 0-58.4%; $p = 0.002$), while HIV-1_{VSV-G} pseudotype infection was unaffected (mean 5.25% \pm 10.7, $p = 0.640$) (Figure 7B). dCM from 5 out of 7 donors reduced X4 HIV-1_{HxB2} pseudotype infection, but not significantly (mean 15.2% \pm 13.1, range 0-68%; $p = 0.289$).

Altogether, these results indicated that decidual culture supernatants participated in the inhibition of HIV-1 entry.



Discussion

This study suggests that soluble factors secreted by decidual cells can inhibit HIV-1 infection. We first show that decidual mononuclear cells produce soluble factors known to modulate HIV-1 infection. Decidual cells were cultured without exogenous stimulation, contrary to some other studies [28,29]. The types and levels of the cytokines detected in decidual mononuclear cell supernatants were similar to those found in decidual histoculture supernatants (data not show), suggesting that the

isolation and culture procedure did not significantly modify the secretion profile. Decidual soluble factors include cytokines known to stimulate HIV-1 infection by promoting inflammation and viral replication including IL-12, TFN- α , IL-6 and IL-8 [6,30,31], but also anti-inflammatory (IL-10) and antiviral cytokines (IFN- α , IFN- γ , CXCL-12, CCL-3, CCL-4 and CCL-5) that inhibit HIV-1 infection [3,4,32,33]. Interestingly, it has been reported that the placenta secretes similar profiles of pro- and anti-inflammatory cytokines to those observed here with the decidua [34,35]. At the maternofetal interface, this pro- and anti-inflammatory balance stimulates leukocyte recruitment and angiogenesis, and regulates placental trophoblast invasion during pregnancy. Moreover, this balance is described in other mucosae such as the gut mucosa, where it is known to regulate microflora tolerance and to prevent pathogen invasion [36].

We have previously shown that decidual mononuclear cells are permissive for HIV-1 infection *in vitro* [24]. Here, we found that secretion of the β -chemokines CCL-3 and CCL-4 was significantly upregulated during R5 HIV-1 infection of decidual mononuclear cells, but not during X4 HIV-1 infection. Some viral proteins, such as Nef, are known to induce β -chemokine production [37]. R5 HIV-1 replicates more efficiently than X4 HIV-1 in decidual cells [24]. The observed increase in β -chemokine secretion during R5 HIV-1 infection could therefore be due to HIV-1 replication. Similar β -chemokine upregulation during HIV-1 infection has also been described in other tissue types, such as lymph nodes and gut-associated lymphoid tissue [38]. This increased β -chemokine secretion was suspected of promoting viral dissemination during the primary infection, through recruitment of immune cells, including HIV-1 target cells [38]. On the other hand, elevated β -chemokine production could also participate in the control of HIV-1 spread, as these soluble factors have been reported to inhibit cell-to-cell HIV-1 infection [23]. Moreover, CCL-3, CCL-4 and CCL-5 are known to inhibit R5 HIV-1 entry by competitively binding CCR5 [3]. β -chemokines might limit the number of infected cells within the decidua and such limit the risk of transmission to the fetus due to the contact of decidual infected cell and placental trophoblast cells. We found that the main source of CCL-3 and CCL-4 in the decidua was CD14⁺ cells. We detected no CCL-5 production by purified dNK cells or decidual CD14⁺ cells when using flow cytometry, while small amounts of CCL-5 were detected in both cultures when we used Luminex technology. We have previously shown that dAPC CD14⁺ cells are the main decidual cell target of R5 HIV-1 [24]. Thus, secretion of HIV-1-inhibiting factors by these cells could constitute a mechanism of autocrine protection, as previously described with peripheral CD4⁺ T lymphocytes [39]. The latter authors found that CD4⁺ T lymphocytes, which

produce the chemokine CCL-4, were 10 times less infected *in vivo* than cells that did not produce CCL-4.

Decidual soluble factors inhibited R5 HIV-1 infection; and, to a lesser extent, X4 HIV-1 infection, variably from one donor to another. In addition, R5 HIV-1 inhibition was higher at day 7 than at day 10, pointing to an effect on the viral entry step. Similarly, X4 HIV-1 inhibition was weaker at day 14 than at day 10, while no significant replication was noted at day 7. We have previously shown that X4 HIV-1 infects decidual mononuclear cells less efficiently than R5 HIV-1 [24]. To confirm that decidual soluble factors inhibit the viral entry step, we used HIV-1 pseudotypes. Decidual soluble factors inhibited the entry of HIV-1 pseudotypes bearing the HIV-1 (R5 or X4) envelope but not the entry of the VSV-G-bearing HIV-1 pseudotype, which is independent of receptor usage. Inhibitory activity did not correlate directly with the level of CCL-3, CCL-4 or CCL-5, or with the total amount of β -chemokines (data not shown). However, we assayed the chemokines in cell supernatants, and it is conceivable that decidual cells consume a proportion of the β -chemokines they secrete. Furthermore, other decidual soluble factors might also be involved in inhibiting HIV-1 infection, possibly in synergy with β -chemokines. Antimicrobial peptides can inhibit HIV-1 entry in target cells [40-43], and have been detected in human decidua [44] and the female reproductive tract [45,46]. High levels of antimicrobial peptides have been detected in vaginal secretions from HIV-1-exposed but uninfected individuals [47] and have been linked to a low rate of mother-to-child transmission [48].

Inhibition of HIV-1 infection by decidual soluble factors including β -chemokines, appears to constitute a protective mechanism. In view of the large inter-individual differences in the degree of viral inhibition observed here, other mechanisms might contribute to the control of HIV-1 transmission at the maternofetal interface. We found that dNK cells also produced CCL-3, CCL-4 and CCL-5, suggesting that they could have a role in the control of HIV-1 transmission. A recent study has shown that NK cells from non-pregnant uterine mucosa can inhibit X4 HIV-1 infection by secreting high levels of CXCL-12 [49]. NK cells are the main decidual immune cell population [20] and cross-talk with dAPC appears to be crucial for maintenance of pregnancy [50-52]. Interactions between dNK cells and dAPC might stimulate the production of anti-HIV-1 factors and thus enhance autocrine protection of target cells.

Conclusion

We report that decidual mononuclear cells naturally produce large amounts of chemokines, and that R5 HIV-1 infection significantly enhances production of the β -chemokines CCL-3 and CCL-4. The main source of

these chemokines was decidual CD14⁺ antigen-presenting cells, which are also the main decidual target cell for R5 HIV-1. Furthermore, we provide evidence that decidual soluble factors, including β -chemokines, participate in inhibiting HIV-1 entry in the decidua. These findings also suggest that the first trimester maternofetal interface is a relevant model for studying determinants of natural protection against mucosal HIV-1 infection.

Materials and methods

Human decidual tissue

Decidual tissue samples were obtained from healthy women undergoing voluntary termination of pregnancy during the first trimester (6-10 weeks) at Antoine Bécélère Hospital, Clamart, France and Tenon Hospital, Paris, France. All the women gave their written informed consent to the use of their tissues. The study was approved by the ethics committee of Hôtel Dieu, Paris, France, the Assistance Publique des Hôpitaux de Paris (n° VAL/2006/06-41/01) and the Biomedical Research Committee of the Institut Pasteur, Paris, France (n° RBM/2005.024).

Histocultures of decidua parietalis and decidua basalis were performed as previously described by Marlin et al [24].

For cell isolation, freshly isolated decidual tissue was minced into small fragments and digested for 1 hour at 37°C under agitation in RPMI 1640 culture medium (Gibco) with 1 mg/ml collagenase IV (Sigma, St Quentin Fallavier, France) and 50 U/ml recombinant DNase I (Roche, Meylan, France). The cell suspension was successively filtered through 100 μ m, 70 μ m and 40 μ m pore-size sterile nylon cell strainers (BD Biosciences, Le pont de Claix, France). The mononuclear cell population was isolated with Lymphocyte Separation Medium (PAA) and cultured in the rich culture media Ham F12: DMEM Glutamax (v:v) (Gibco) supplemented with 15% foetal calf serum (PAA, Les Mureaux, France), penicillin (0.1 U/l) and streptomycin (1×10^{-8} g/l) (Gibco). CD14⁺ and NK cells were purified with anti-CD14 and anti-CD56 magnetic beads, respectively, as recommended by the manufacturer (Miltenyi, Paris, France).

HIV-1 primary isolates and pseudotypes

Decidual histocultures and decidual mononuclear cells were infected with two HIV-1 primary isolates, HIV-1_{BaL} and HIV-1_{LAI} (with R5 or X4 tropism respectively). The isolates were amplified on PHA-stimulated PBMC from two blood donors for 10 days. PBMC cultures were maintained in RPMI 1640 Glutamax (Gibco) supplemented with 10% fetal calf serum, penicillin, streptomycin and 100 U/ml recombinant interleukin-2 (Chiron-Nederlands). Virions were concentrated by centrifugation on Vivaspin 100 000 Kda (Sartorius, Palaiseau, France) at 1400 g for 40 minutes.

Luciferase-expressing viral pseudotypes were based on the NL4-3 HIV-1 and VSV-G (amphotropic), BaL (R5) or HxB2 (X4) env plasmids [53-55]. The viral pseudotypes were generated by transfecting HEK-293T cells with the corresponding cDNA plasmid (pNL4-3 Δ EnvLuc+ plus the appropriate env cDNA) using the transfection reagent SuperFect transfection reagent (Qiagen) as directed by the manufacturer. The pNL4-3 Δ EnvLuc+ lacks the *nef* gene and the resulting pseudotype is non replicative. Supernatants were collected 72 hours after transfection, assayed for the viral pseudotypes by means of p24 antigen ELISA (Zeptomatrix) and titrated on HeLa P4P cells. The efficiency of infection by the viral pseudotypes was determined by measuring luciferase expression with Luciferase Reagent (Promega) and a Glomax luminometer.

Immunohistochemistry

Decidual sections were obtained by embedding freshly isolated decidual tissue in Tissue-Tek (Sakura, Gentaur, Paris, France) and snap-frozen in an isopentane/liquid nitrogen bath. Frozen Tissue-Tek blocks were cut with a cryostat and frozen sections (5 μ m thick) were fixed in acetone and rehydrated in TBS (Dako, Trappes, France). Tissue sections were stained for CD14 (RMO52, Beckman Coulter), CD3 (F7.2.38, Dako), CD34 (QbEnd10, Beckman Coulter), CD56 (N901, Beckman Coulter) or Cytokeratin 7 (OV-TL 12/30, Dako). Endogenous peroxidase and alkaline phosphatase (AP) were blocked for 10 minutes by addition of hydrogen peroxide and levamisole (Dako). Surface markers were visualized using the Envision+ dual link system (Dako), or using biotin-streptavidin-alkaline phosphatase complex and Vector Red (Abcys, Paris, France), as an AP substrate. Tissue sections were counterstained with haematoxylin (Labonord, templars, France), mounted in permanent medium and analysed with a Nikon Eclipse 80i microscope.

Cytokine assays

The main cytokines involved in the regulation of HIV-1 infection, namely IL-2, IL-10, IL-12, IL-15, TNF- α , IFN- α , IFN- γ , CCL-3 (MIP1- α), CCL-4 (MIP1- β), CCL-5 (RANTES), IL-6, IL-8, CXCL-10 (IP10) and CCL-2 (MCP1) were measured by Luminex assay (Human Cytokine 25-plex antibody bead kit, Invitrogen Corporation, Carlsbad, California). CXCL-12 (SDF1) was measured with the Human SDF1 Quantikine Immunoassay (R & D System, Minneapolis) in the manufacturer's recommended conditions. The cytokines were measured in supernatants of unstimulated decidual mononuclear cells collected after 24 hours of culture, or after 72 hours in the case of purified dAPC CD14⁺ and dNK cells, when cytokine concentrations were maximal in the culture supernatants. To compare cytokine production by infected and non-infected decidual mononuclear cells, 3-days of cultured

supernatants (day 11 to day 14) were assayed 14 days after infection with or without HIV-1_{BaL} or HIV-1_{LAI}.

Identification of cytokine-producing cells

Decidual mononuclear cells were tested for chemokine production by flow cytometry. After isolation, cells were cultured for 16 hours with Brefeldin A (Sigma-Aldrich) at 5 µg/ml, then labelled with anti-CD45-Amcyan, anti-CD14-Pacific Blue, anti-CD4-PE-Cy7, anti-CD56-Alexa 700 (Becton Dickinson), anti-CD3-PE-TexasRed and anti-CD8-APC (Beckman Coulter) before fixation and permeabilisation with the Intraprep reagent (Beckman Coulter). The cells were then labelled with anti-CCL-3-FITC, anti-CCL-4-FITC, anti-CCL-5-FITC (R & D System, Minneapolis) or IgG-FITC (control). Flow cytometry was performed with an LSRII device (Becton Dickinson) and FlowJo 9.0.1 software.

HIV-1 infection

Decidual mononuclear cells were incubated for 1 hour with HIV-1 isolates or uninfected PBMC supernatant, at 10⁻³ MOI, then washed 3 times and cultured at 10⁶ cells/ml. Viral production was measured every 3 or 4 days by detection of p24 antigen in cell culture supernatants by ELISA (Zeptometrix).

Inhibition of viral production

To examine the influence of the cytokine environment on the inhibition of viral replication, decidual mononuclear cells were cultured for 24 hours before infection with HIV-1_{BaL} or HIV-1_{LAI}. After 24 hours, the cells were infected with 10⁻⁴ MOI for 1 hour at 37°C following or not a washing step. After 3 washes post-infection, the cultured cells were resuspended in culture medium and HIV-1 p24 antigen was titrated by ELISA in the culture supernatants at day 7 and day 10.

HIV-1 entry inhibition assays

HeLa P4P cells (CD4⁺ CCR5⁺ CXCR4⁺) [56] were seeded at 10⁴ cells/well and cultured for 24 hours in 96-well plates. Entry inhibition assays were performed by incubating the cells for 1 hour with 100 µl of decidual conditioned medium collected after 24 h of decidual mononuclear cell culture, or with fresh culture medium (Mock medium), followed by treatment with 6 ng of p24 equivalent of each HIV pseudotype for 1 hour. The cells were then washed in 1X phosphate buffered saline (PBS) and cultured for 72 hours at 37°C. HeLa P4P cells were washed in 1X PBS and lysed with 100 µl of Cell Lysis Buffer (Promega). The cell lysates (10 µl) were used to determine luciferase activity as described above. Results are expressed as Relative Light Units (RLU)/100 µl of lysate. Each experimental condition was performed in triplicate.

Statistical analysis

Each condition was tested in at least four independent experiments. The one-sample t test was used. The hypothetical value was 1 for the fold-change graph and 0 for the percentage inhibition graph. Significance was assumed at p < 0.05. Prism 4 software (Graph Pad) was used for all analyses.

Acknowledgements and funding

The authors thank Dr Charles Wira for useful discussions, David Young for critical editing of the manuscript, all the women who gave their informed consent, Dr Claire de Truchis and the clinical staff of the participating institutions (Assistance Publique-Hôpitaux de Paris, AP-HP) for providing the biological samples. The authors also acknowledge the Center for Human Immunology at Institut Pasteur for its support with Luminex experiments, the PIRC (Pole Intégré de Recherche Clinique) at Institut Pasteur for their help in the biomedical regulatory aspects of the project and the SESAME program for the LSRII device funding.

This work was supported by Institut Pasteur, INSERM and AP-HP and by grants from ANRS (#2008/062) and Sidaction (#5007-05-00/AO17-2). RM was a recipient of the "Ministère de l'Enseignement supérieur et de la Recherche" and Sidaction fellowships. MD is a recipient of a Sidaction fellowship.

Author details

¹Regulation of Retroviral Infection Unit, Department of virology, Institut Pasteur, Paris, France. ²Gynecology-Obstetrics Service, A. Béclière Hospital, AP-HP, Clamart, France. ³Department of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, UMP, Paris, France.

Authors' contributions

Conceived and designed the experiments: RM MTN FBS EM. Performed the experiments: RM MTN MD CC. Analyzed the data: RM MTN FBS EM. Contributed to materials: ALB NB. Wrote the paper: RM MTN MD EM. All authors read and approved the final manuscript.

Conflicts of interests

The authors declare that they have no competing interests.

Received: 5 April 2011 Accepted: 18 July 2011 Published: 18 July 2011

References

1. Schroder HC, Kelve M, Muller WE: The 2-5A system and HIV infection. *Prog Mol Subcell Biol* 1994, **14**:176-197.
2. Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS: Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. *Virology* 1993, **193**:138-148.
3. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. *Science* 1995, **270**:1811-1815.
4. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* 1996, **272**:872-877.
5. Foli A, Saville MW, Baseler MW, Yarchoan R: Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. *Blood* 1995, **85**:2114-2123.
6. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, Stanley S, Fauci AS: Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. *J Exp Med* 1990, **172**:151-158.
7. Munoz-Fernandez MA, Navarro J, Garcia A, Punzon C, Fernandez-Cruz E, Fresno M: Replication of human immunodeficiency virus-1 in primary human T cells is dependent on the autocrine secretion of tumor necrosis factor through the control of nuclear factor-kappa B activation. *J Allergy Clin Immunol* 1997, **100**:838-845.

8. Makrigiannakis A, Minas V, Kalantaridou SN, Nikas G, Chrousos GP: **Hormonal and cytokine regulation of early implantation.** *Trends Endocrinol Metab* 2006, **17**:178-185.
9. Dubinsky V, Poehlmann TG, Suman P, Gentile T, Markert UR, Gutierrez G: **Role of regulatory and angiogenic cytokines in invasion of trophoblastic cells.** *Am J Reprod Immunol* 2009, **63**:193-199.
10. von Rango U: **Fetal tolerance in human pregnancy—a crucial balance between acceptance and limitation of trophoblast invasion.** *Immunol Lett* 2008, **115**:21-32.
11. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H: **Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.** *J Clin Invest* 1994, **94**:2060-2067.
12. Ometto L, Zanotto C, Maccabruni A, Caselli D, Truscia D, Giaquinto C, Ruga E, Chieco-Bianchi L, De Rossi A: **Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission.** *AIDS* 1995, **9**:427-434.
13. Salvatori F, Scarlatti G: **HIV type 1 chemokine receptor usage in mother-to-child transmission.** *AIDS Res Hum Retroviruses* 2001, **17**:925-935.
14. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL: **Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.** *Science* 1992, **255**:1134-1137.
15. Ahmad N, Baroudy BM, Baker RC, Chappay C: **Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission.** *J Virol* 1995, **69**:1001-1012.
16. Matala E, Hahn T, Yedavalli VR, Ahmad N: **Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission.** *AIDS Res Hum Retroviruses* 2001, **17**:1725-1735.
17. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M: **Mother-to-child transmission of HIV-1: timing and implications for prevention.** *Lancet Infect Dis* 2006, **6**:726-732.
18. Moffett A, Loke C: **Immunology of placentation in eutherian mammals.** *Nat Rev Immunol* 2006, **6**:584-594.
19. Williams PL: **Fetal membranes and placenta.** *Gray's anatomy The anatomical basis of medicine and surgery* Churchill Livingstone; 1995, 158-166.
20. Trundley A, Moffett A: **Human uterine leukocytes and pregnancy.** *Tissue Antigens* 2004, **63**:1-12.
21. Dolcini G, Derrien M, Chaouat G, Barre-Sinoussi F, Menu E: **Cell-free HIV type 1 infection is restricted in the human trophoblast choriocarcinoma BeWo cell line, even with expression of CD4, CXCR4 and CCR5.** *AIDS Res Hum Retroviruses* 2003, **19**:857-864.
22. Douglas GC, Fry GN, Thirkill T, Holmes E, Hakim H, Jennings M, King BF: **Cell-mediated infection of human placental trophoblast with HIV in vitro.** *AIDS Res Hum Retroviruses* 1991, **7**:735-740.
23. Derrien M, Faye A, Dolcini G, Chaouat G, Barre-Sinoussi F, Menu E: **Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro.** *J Virol* 2005, **79**:12304-12310.
24. Marlin R, Nugeyre MT, de Truchis C, Berkane N, Gervaise A, Barre-Sinoussi F, Menu E: **Antigen-presenting cells represent targets for R5 HIV-1 infection in the first trimester pregnancy uterine mucosa.** *PLoS ONE* 2009, **4**:e5971.
25. von Rango U, Classen-Linke I, Kertschanska S, Kemp B, Beier HM: **Effects of trophoblast invasion on the distribution of leukocytes in uterine and tubal implantation sites.** *Fertil Steril* 2001, **76**:116-124.
26. Bulmer JN, Williams PJ, Lash GE: **Immune cells in the placental bed.** *Int J Dev Biol* 2010, **54**:281-294.
27. King A, Jokhi PP, Smith SK, Sharkey AM, Loke YW: **Screening for cytokine mRNA in human villous and extravillous trophoblasts using the reverse-transcriptase polymerase chain reaction (RT-PCR).** *Cytokine* 1995, **7**:364-371.
28. Vacca P, Cantoni C, Prato C, Fulcheri E, Moretta A, Moretta L, Mingari MC: **Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells.** *Int Immunol* 2008.
29. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, et al: **Decidual NK cells regulate key developmental processes at the human fetal-maternal interface.** *Nat Med* 2006, **12**:1065-1074.
30. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS: **Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.** *Proc Natl Acad Sci USA* 1989, **86**:2365-2368.
31. Al-Harthi L, Roebuck KA, Landay A: **Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production.** *J Clin Immunol* 1998, **18**:124-131.
32. Kollmann TR, Pettoello-Mantovani M, Katopodis NF, Hachamovitch M, Rubinstein A, Kim A, Goldstein H: **Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver.** *Proc Natl Acad Sci USA* 1996, **93**:3126-3131.
33. Shirazi Y, Pittha PM: **Interferon alpha-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells.** *Virology* 1993, **193**:303-312.
34. Faye A, Pornprasert S, Dolcini G, Ave P, Taieb J, Taupin JL, Derrien M, Huerre M, Barre-Sinoussi F, Chaouat G, Menu E: **Evaluation of the placental environment with a new in vitro model of histocultures of early and term placentae: determination of cytokine and chemokine expression profiles.** *Placenta* 2005, **26**:262-267.
35. Moussa M, Mognetti B, Dubanchet S, Menu E, Roques P, Dormont D, Barre-Sinoussi F, Chaouat G: **Expression of beta chemokines in explants and trophoblasts from early and term human placentae.** *Am J Reprod Immunol* 2001, **46**:309-317.
36. Izcue A, Coombes JL, Powrie F: **Regulatory lymphocytes and intestinal inflammation.** *Annu Rev Immunol* 2009, **27**:313-338.
37. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, Stevenson M: **HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages.** *Nat Med* 1999, **5**:997-1003.
38. Nilsson J, Kinloch-de-Loes S, Granath A, Sonnerborg A, Goh LE, Andersson J: **Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection.** *Aids* 2007, **21**:565-574.
39. Casazza JP, Brenchley JM, Hill BJ, Ayana R, Ambrozak D, Roederer M, Douek DC, Betts MR, Koup RA: **Autocrine production of beta-chemokines protects CMV-specific CD4 T cells from HIV infection.** *PLoS Pathog* 2009, **5**:e1000646.
40. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: **Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.** *J Exp Med* 2004, **200**:1337-1346.
41. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: **Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.** *Blood* 1997, **90**:1141-1149.
42. Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR: **Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract.** *Immunology* 2009.
43. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P: **Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4.** *Blood* 2007, **109**:2928-2935.
44. King AE, Critchley HO, Kelly RW: **Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role.** *Mol Hum Reprod* 2000, **6**:191-196.
45. Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP: **Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections.** *Am J Obstet Gynecol* 2000, **183**:1243-1248.
46. King AE, Critchley HO, Kelly RW: **Innate immune defences in the human endometrium.** *Reprod Biol Endocrinol* 2003, **1**:116.
47. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachiki C, Pak BJ, Podust VN, Broliden K, Hirbod T, et al: **Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition.** *Aids* 2009, **23**:1669-1677.
48. Pillay K, Coutoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: **Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission.** *J Infect Dis* 2001, **183**:653-656.

49. Mselle TF, Howell AL, Ghosh M, Wira CR, Sentman CL: **Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12.** *J Virol* 2009, **83**:11188-11195.
50. Dietl J, Honig A, Kammerer U, Rieger L: **Natural killer cells and dendritic cells at the human feto-maternal interface: an effective cooperation?** *Placenta* 2006, **27**:341-347.
51. Verma S, Hiby SE, Loke YW, King A: **Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15.** *Biol Reprod* 2000, **62**:959-968.
52. Laskarin G, Redzovic A, Rubesa Z, Mantovani A, Allavena P, Haller H, Vlastelic I, Rukavina D: **Decidual natural killer cell tuning by autologous dendritic cells.** *Am J Reprod Immunol* 2008, **59**:433-445.
53. Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS: **High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.** *J Virol* 1996, **70**:2581-2585.
54. Connor RI, Chen BK, Choe S, Landau NR: **Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.** *Virology* 1995, **206**:935-944.
55. Landau NR, Page KA, Littman DR: **Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.** *J Virol* 1991, **65**:162-169.
56. Verrier FC, Charneau P, Altmeyer R, Laurent S, Borman AM, Girard M: **Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.** *Proc Natl Acad Sci USA* 1997, **94**:9326-9331.

doi:10.1186/1742-4690-8-58

Cite this article as: Marlin *et al.*: Decidual soluble factors participate in the control of HIV-1 infection at the maternofetal interface. *Retrovirology* 2011 **8**:58.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

